Related Experiment Videos
Glioblastoma multiforme and hepatitis B: do the right thing(s)
F Purchiaroni1, P Begini, G Minniti
1Department of Digestive and Liver Disease, School of Medicine and Psychology, Sapienza University, Azienda Ospedaliera S. Andrea, Rome, Italy. flaminia.purchiaroni@hotmail.it.
European Review for Medical and Pharmacological Sciences
|December 24, 2014
Summary
Hepatitis B virus (HBV) reactivation can occur during glioblastoma treatment with temozolomide (TMZ). Prophylactic antiviral therapy is crucial to prevent severe hepatitis B relapse in patients undergoing TMZ treatment.
Area of Science:
- Oncology
- Hepatology
- Virology
Background:
- Hepatitis B virus (HBV) reactivation is a known risk with immunosuppression.
- Temozolomide (TMZ) is a key treatment for glioblastoma multiforme (GBM).
- HBV reactivation can cause mild hepatitis to acute liver failure.